In phase 3 trials, the first agent in a novel class known as the selective cannabinoid type 1 receptor blockers doubled the odds of quitting smoking while reducing post-cessation weight gain compared with placebo. The agent, rimonabant, also improved several features of the metabolic syndrome in patients with abdominal obesity, reported researchers at the 53rd Annual Scientific Session of the American College of Cardiology (ACC).

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

New class may help smokers quit, curb post-cessation weight gain

Newsletter